Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05242471 · ClinicalTrials.gov registry record · Phase 2

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 2 study of Crohn's Disease, sponsored by Janssen Research & Development.

Active
Registry status
Phase 2
Development phase
703
Enrollment target
20
Study locations

NCT05242471 is a Phase 2 study of Crohn's Disease that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 703 participants, below the 2,408-participant average among 104 other Crohn's Disease trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05242471, a Phase 2 study of Crohn's Disease, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
703 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Conditions Studied

Crohn's Disease

Interventions

  • DRUG Placebo
  • BIOLOGICAL Guselkumab
  • BIOLOGICAL Golimumab
  • BIOLOGICAL JNJ-78934804

Study Locations (20)

California

  • Om Research LLC - Apple Valley
  • Valley Gastroenterology Medical Group - Arcadia
  • Southern California Research Center - Coronado
  • Desert Gastroenterology Associates - Lancaster
  • Cedars Sinai Medical Center - Los Angeles
  • UCLA - Los Angeles
  • Hoag Memorial Hospital - Newport Beach
  • UCI Irvine Medical Center - Orange
  • Medical Associates Research Group, Inc. - San Diego
  • University of California San Francisco - San Francisco

Florida

  • Pioneer Research Solutions Inc. - Coconut Creek
  • Homestead Associates in Research Inc - Homestead
  • Osceola Mental Health D/B/A Park Place Behavioral Health Care - Kissimmee

Connecticut

  • Medical Research Center of Connecticut - Hamden
  • Yale University School Of Medicine - New Haven

Alabama

  • University of Alabama Liver Center - Birmingham

Arizona

  • Del Sol Research Management, LLC - Tucson

Arkansas

  • Moore Clinical Trials, LLC - Little Rock

Colorado

  • University of Colorado - Aurora

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 703 participants
Start Date 2022-07-22
Est. Completion 2029-11-05
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05242471

The ClinicalTrials.gov registry entry for NCT05242471 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 703 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,408-participant average among 104 other Crohn's Disease trials with a reported enrollment target (71% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT05242471 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05242471 about?

NCT05242471 is a clinical study titled "A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

What is the current status of trial NCT05242471?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 703 participants. The study started on 2022-07-22. Estimated completion is 2029-11-05.

What conditions does trial NCT05242471 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT05242471?

The interventions under investigation include: Placebo (DRUG), Guselkumab (BIOLOGICAL), Golimumab (BIOLOGICAL), JNJ-78934804 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05242471?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05242471 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.